Related Experiment Video
Updated: Oct 25, 2025
08:09
Tubal Cytology of the Fallopian Tube as a Promising Tool for Ovarian Cancer Early Detection
Published on: July 25, 2017
12.5K
Future Screening Prospects for Ovarian Cancer
Diana Žilovič1,2,3, Rūta Čiurlienė3, Rasa Sabaliauskaitė4
1Life Sciences Center, Institute of Biosciences, Vilnius University, Saulėtekio Avenue 7, LT-10222 Vilnius, Lithuania.
Cancers
|August 7, 2021
Summary
Current ovarian cancer (OC) diagnostics lack sensitivity for early detection. Liquid biopsies show promise for early diagnosis by analyzing biomarkers like circulating tumor cells and cell-free DNA in blood or urine.
Area of Science:
- Oncology
- Biomarker Discovery
- Molecular Diagnostics
Background:
- Current ovarian cancer (OC) diagnostic tools, including transvaginal ultrasound and biomarkers CA 125 and HE4, exhibit insufficient sensitivity and specificity for early-stage detection.
- The absence of early symptoms and effective screening strategies for asymptomatic populations contributes to poor patient prognosis in OC.
- There is an urgent need for novel diagnostic and screening methods to facilitate early OC diagnosis and improve outcomes.
Purpose of the Study:
- To review recent advancements in molecular biomarkers for early ovarian cancer detection.
- To specifically evaluate the diagnostic efficacy of liquid biopsy methods in identifying early-stage OC.
- To highlight the potential of non-invasive liquid biopsies for cancer screening and diagnosis.
Main Methods:
- Systematic analysis of recent scientific literature focusing on molecular biomarkers for OC.
- Emphasis on liquid biopsy techniques utilizing plasma/serum, uterine lavage, and urine samples.
- Detection of specific circulating biomarkers including circulating tumor cells (CTCs), cell-free DNA (cfDNA), small noncoding RNAs, and tumor-educated platelets (TEPs).
Main Results:
- Liquid biopsy approaches offer a promising non-invasive strategy for early cancer detection.
- Analysis of circulating tumor cells, cfDNA, small noncoding RNAs, and TEPs are key areas of investigation for OC biomarkers.
- Recent studies demonstrate the potential of these biomarkers in liquid samples for improving OC diagnostic accuracy.
Conclusions:
- Liquid biopsies represent a significant advancement in the pursuit of non-invasive diagnostic and screening tools for ovarian cancer.
- Further research into the identified molecular biomarkers within liquid biopsies is crucial for clinical implementation.
- The development of effective liquid biopsy-based strategies could revolutionize early OC detection and patient management.
